Cipher Pharmaceuticals Inc. (TSX:CPH)

Market Cap	471.48M +45.5%
Revenue (ttm)	69.17M +51.2%
Net Income	37.47M +136.7%
EPS	1.44 +128.3%
Shares Out	25.31M
PE Ratio	12.94
Forward PE	18.50
Dividend	n/a
Ex-Dividend Date	n/a

Volume	20,606
Average Volume	46,976
Open	18.13
Previous Close	18.05
Day's Range	18.13 - 18.80
52-Week Range	10.61 - 19.59
Beta	0.52
RSI	64.99
Earnings Date	Mar 12, 2026

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the manage...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2000
• Employees: 5
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: CPH

Financial Performance

In 2025, Cipher Pharmaceuticals's revenue was $50.45 million, an increase of 51.22% compared to the previous year's $33.36 million. Earnings were $27.33 million, an increase of 136.72%.

Financial numbers in USD